US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

82.45

+1.311.61%

Post-market: 82.450.00000.00%19:30 EDT

Volume:159.48K

Turnover:13.12M

Market Cap:3.57B

PE:- -

High:82.56

Open:80.98

Low:80.93

Close:81.14

52wk High:85.46

52wk Low:67.77

Shares:43.35M

Float Shares:43.35M

Volume Ratio:0.63

T/O Rate:0.37%

Dividend:1.01

Dividend Rate:1.23%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live

2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders

Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Actinogen Medical Adds Modest Number of New Shares to ASX Listing

Marvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/FHLC/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FHLC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FHLC\",,,,,undefined,":{"symbol":"FHLC","market":"US","secType":"STK","nameCN":"Fidelity MSCI Health Care Index ETF","latestPrice":82.45,"timestamp":1791576000000,"preClose":81.14,"halted":0,"volume":159477,"hourTrading":{"tag":"盘后","latestPrice":82.45,"preClose":82.45,"latestTime":"19:30 EDT","volume":40,"amount":3289.09,"timestamp":1791588606641,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016144934680798646,"floatShares":43350000,"shares":43350000,"eps":0,"marketStatus":"Market Closed","change":1.31,"latestTime":"10-09 16:00:00 EDT","open":80.98,"high":82.56,"low":80.93,"amount":13118699.222520001,"amplitude":0.020089,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":81.14,"sharesOutstanding":39450000,"nav":82.438885,"aum":3660286494,"dividendRate":0.012302,"bidAskSpread":0.000393,"preHourTrading":{"tag":"盘前","latestPrice":81.42,"preClose":81.14,"latestTime":"08:48 EDT","volume":211,"amount":17176.34106,"timestamp":1791550123293,"change":0.28,"changeRate":0.003451,"amplitude":0.003451},"postHourTrading":{"tag":"盘后","latestPrice":82.45,"preClose":82.45,"latestTime":"19:30 EDT","volume":40,"amount":3289.09,"timestamp":1791588606641,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6302606688957819,"impliedVol":0.1618,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FHLC\",,,,,undefined,":{"symbol":"FHLC","floatShares":43350000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6302606688957819,"shares":43350000,"dividePrice":1.0143,"high":82.56,"amplitude":0.020089,"preClose":81.14,"low":80.93,"week52Low":67.772,"pbRate":"--","week52High":85.4649,"institutionHeld":0,"latestPrice":82.45,"eps":0,"divideRate":0.012302,"volume":159477,"delay":0,"ttmEps":0,"open":80.98,"prevYearClose":74.28,"prevWeekClose":80.6,"prevMonthClose":81.7,"prevQuarterClose":81.7,"fiveDayClose":80.6,"twentyDayClose":80.3,"sixtyDayClose":78.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FHLC\",params:#limit:5,,,undefined,":[{"date":"2026-09-18","symbol":"FHLC","amount":0.254,"announcedDate":"2026-09-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-18","defaultRemindTime":1789738200000,"name":"Fidelity MSCI Health Care Index","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-22","payableDate":"2026-09-18","currency":"USD","dateTimestamp":1789704000000,"payDate":"2026-09-22"},{"date":"2026-06-18","symbol":"FHLC","amount":0.263,"announcedDate":"2026-06-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Fidelity MSCI Health Care Index","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-23"},{"date":"2026-03-20","symbol":"FHLC","amount":0.229,"announcedDate":"2026-03-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"Fidelity MSCI Health Care Index","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-24","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-24"},{"date":"2025-12-19","symbol":"FHLC","amount":0.272,"announcedDate":"2025-12-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-19","defaultRemindTime":1766154600000,"name":"Fidelity MSCI Health Care Index","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-19","currency":"USD","dateTimestamp":1766120400000,"payDate":"2025-12-23"},{"date":"2025-09-19","symbol":"FHLC","amount":0.256,"announcedDate":"2025-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-19","defaultRemindTime":1758288600000,"name":"Fidelity MSCI Health Care Index","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-19","currency":"USD","dateTimestamp":1758254400000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FHLC\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-22","value":0.117,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-23","value":0.125,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-22","value":0.137,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-20","value":0.132,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.134,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FHLC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FHLC\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671201691","title":"Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671201691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671201691?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:03","pubTimestamp":1790769783,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M0LR:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0225283273.USD","LLII","LU1057294990.SGD","LU1548497426.USD","LU2471134796.USD","SG9999014880.SGD","LU0256863811.USD","SGXZ99366536.SGD","BK4533","LU2211815571.USD","BK4007","PPH","LU2023250504.SGD","RXL","LU1988902786.USD","LU1069344957.HKD","LU2236285917.USD","SG9999018857.SGD","LU2468319806.SGD","LU2552382215.SGD","LU1629891620.HKD","IE00BKPKM429.USD","IE00B1BXHZ80.USD","LU1712237335.SGD","LU1814569148.SGD","SG9999015945.SGD","LU1145028129.USD","LU1366192091.USD","WDNA","LU2491049909.HKD","LU1868837136.USD","SG9999015986.USD","TRUH","IE00BFSS7M15.SGD","LU2750360997.AUD","MEDX","LU1035775433.USD","LU1868836914.USD","CANC","OZEM","LU0417517546.SGD","LU0238689110.USD","IE00BJT1NW94.SGD","LU0210536198.USD","LU0432979614.USD","LU0471298777.SGD","LU0385154629.USD","LU0882574055.USD","LU1280957306.USD","LU2361044949.HKD","MEDI","LU0106261372.USD","BK4585","IE0009355771.USD","LU0820561909.HKD","THNR","LU1989771016.USD","MHIP","SG9999017495.SGD","IE00BWXC8680.SGD","LU1023059063.AUD","LU1061106388.HKD","FTXH","SG9999013999.USD","LU2746668461.USD","SGXZ81514606.USD","LU0158827781.USD","LU2491050154.USD","LU0345770308.USD","LU0353189680.USD","IE0005OL40V9.USD","IE00B7KXQ091.USD","LU2023250330.USD","LU0820562030.AUD","LU0234572021.USD","LU0058720904.USD","ILDR","TMED","LU0471298694.HKD","LU2750360641.GBP","SGXZ51526630.SGD","LU0466842654.USD","LU0820561818.USD","LU2237443549.SGD","BK4534","LU0203201768.USD","SG9999014898.SGD","LU2471134879.HKD","LU0823434583.USD","LU0672654240.SGD","LU2112291526.USD","LU2023251221.USD","LU2168564065.EUR","LU0289739699.SGD","LU2357305700.SGD","LU2360106947.USD","LU2168564495.EUR","IXJ","VHT","LU0823416689.USD","LU0354030511.USD","LU1093756168.USD","LU0787776722.HKD","GB00BDT5M118.USD","IE0004445239.USD","LU2089283258.USD","LU0079474960.USD","LU2462157665.USD","LU0109391861.USD","SG9999015978.USD","LLY","LU0198837287.USD","LU0354030438.USD","LU1064131342.USD","LU0882574139.USD","IE0001KFT4U8.USD","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU1868837300.USD","SGXZ31699556.SGD","LLYZ","LU1623119135.USD","IE00BK4W5L77.USD","LU0320765992.SGD","LU2265009873.SGD","GDOC","LU0708995401.HKD","LU0456855351.SGD","LU0889565916.HKD","SG9999014906.USD","AGNG","IE00B775H168.HKD","LU2271345857.HKD","LU0158827948.USD","LU2602419157.SGD","IE00BKDWB100.SGD","LU1232071149.USD","IE00BJJMRX11.SGD","CURE","LU0683600562.USD","LU1720051017.SGD","SG9999014914.USD","BK4599","LU2106854487.HKD","IE00B1XK9C88.USD","LU1974910355.USD","IYH","BK4588","LU0640476718.USD","LU2237443978.SGD","LU2471134523.USD","LU2108987350.USD","LU1868836591.USD","IE00B4JS1V06.HKD","LU2417539215.USD","LU0786609619.USD","LU2462591350.SGD","LU0943347566.SGD","LU2361044865.SGD","SG9999001176.USD","PJP","XLV","LU0256863902.USD","LU2324357040.USD","LU0006306889.USD","LU0689472784.USD","LU1691799644.USD","LU1720051108.HKD","LU1868836757.USD","IE00BK4W5M84.HKD","LU2168564222.USD","SG9999015952.SGD","ELIL","IE00BJLML261.HKD","LU2168563687.JPY","LU2237443382.USD","IHE","LU2896262040.SGD","LU1979441026.SGD","LU0353189763.USD","LU1291159041.SGD","LU2111349929.HKD","LU2237438978.USD","ELIS","LU1551013342.USD","LU0320765059.SGD","IE00B4R5TH58.HKD","LU1804176565.USD","LU1093756325.SGD","LU0109394709.USD","IE00BN29S564.USD","LU0203202063.USD","LU0323591593.USD","LU2168564149.EUR","LU2089284900.SGD","LU1127390331.HKD","HRTS","LU0964807845.USD","LU2237443895.HKD","LU2746668974.SGD","LU2063271972.USD","IE00B2B36J28.USD","IE0004445015.USD","LU0316494557.USD","SG9999018865.SGD","LU2089984988.USD","LU2552382058.USD","LU1551013425.SGD","IE00BFTCPJ56.SGD","LU2237443465.HKD","LLYX","LU0133085943.USD","IE00BFSS8Q28.SGD","LU1983299246.USD","LU2461242641.AUD","LU2213496289.HKD","LU0094547139.USD","IE0002141913.USD","SGXZ57979304.SGD","LU0823434740.USD","LU2471134952.CNY","LU2756315664.SGD","LU2756315318.SGD","LU0266013472.USD","BK4581","LU0174119429.USD","LU1917777945.USD","LU2028103732.USD","LU2264538146.SGD","FHLC","SG9999001176.SGD","LU2456880835.USD","LU2087625088.SGD","LU2237443622.USD","LU0345770993.USD","LU2361045086.USD","JDOC","LU0061475181.USD","BK4516","LU0096364046.USD","LU2491050071.SGD","LU2552382132.HKD","LU0097036916.USD","LU0114720955.EUR","LU0122379950.USD","IE00BJJMRY28.SGD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671016922","title":"Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671016922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671016922?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:03","pubTimestamp":1790769783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M0LR:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","LU0787776722.HKD","SG9999018865.SGD","ILDR","BK4516","BK4599","ELIS","LU1983299246.USD","LU2237443622.USD","SGXZ81514606.USD","LU2462157665.USD","LU2168564149.EUR","LU2089284900.SGD","LU2168564065.EUR","LU1623119135.USD","LU2023250330.USD","SG9999015952.SGD","IE00B1XK9C88.USD","LU1720051017.SGD","LU0256863902.USD","LU2750360641.GBP","SGXZ31699556.SGD","PJP","MEDX","LU0823416689.USD","LU0109391861.USD","SG9999017495.SGD","LU1712237335.SGD","LU0006306889.USD","GB00BDT5M118.USD","LU0174119429.USD","LU1291159041.SGD","SG9999013999.USD","LU0786609619.USD","LU2471134879.HKD","LU1232071149.USD","LU1868837300.USD","SG9999014906.USD","THNR","LU0354030511.USD","AGNG","IE00B775H168.HKD","LU2471134523.USD","LU2471134796.USD","LU2063271972.USD","LU0708995401.HKD","IE00BFSS8Q28.SGD","LU2106854487.HKD","LU2491049909.HKD","SG9999014880.SGD","LU2324357040.USD","LU2746668461.USD","LU1551013425.SGD","LU0198837287.USD","LU0061475181.USD","IE00B4JS1V06.HKD","LU1366192091.USD","IE00BK4W5M84.HKD","IE0004445015.USD","IE00BKDWB100.SGD","LU0432979614.USD","LU1974910355.USD","LU0097036916.USD","LU2361045086.USD","LU2111349929.HKD","LU2211815571.USD","SG9999015978.USD","IE00BFSS7M15.SGD","LU0203202063.USD","LU2089283258.USD","LU0683600562.USD","LU0820561909.HKD","LU0320765059.SGD","LU1323610961.USD","LU1093756325.SGD","SGXZ57979304.SGD","OZEM","LU2552382215.SGD","LU0820562030.AUD","HRTS","LLYX","LU1548497426.USD","LU0158827781.USD","LU0210536198.USD","LU0079474960.USD","LLII","LU0385154629.USD","IE00BJJMRY28.SGD","CURE","LU1551013342.USD","CANC","LU0466842654.USD","LU1061106388.HKD","LU2357305700.SGD","IHE","LU0417517546.SGD","LU2746668974.SGD","LU0234572021.USD","LU0456855351.SGD","SG9999014898.SGD","LU2360106947.USD","LU0889565916.HKD","LU1280957306.USD","LLY","LU1804176565.USD","IE00BJJMRZ35.SGD","IE0001KFT4U8.USD","BK4534","LU1145028129.USD","LU0823434583.USD","LU1023059063.AUD","LU1868836757.USD","LU0289739699.SGD","LU0345770308.USD","LU0820561818.USD","LU1720051108.HKD","LU1127390331.HKD","LU2417539215.USD","LU2552382132.HKD","LU2750360997.AUD","XLV","LU0225283273.USD","MEDI","TMED","IE00BFTCPJ56.SGD","LU0943347566.SGD","SG9999015945.SGD","LU2087625088.SGD","BK4588","IE00BK4W5L77.USD","LU0114720955.EUR","LU1035775433.USD","LU2756315664.SGD","LU1267930730.SGD","LU2552382058.USD","LU1814569148.SGD","LU2023250504.SGD","IE00BJJMRX11.SGD","LU2471134952.CNY","LU0471298777.SGD","LU1868836591.USD","LU2236285917.USD","VHT","LU0094547139.USD","LU1691799644.USD","IE00B4R5TH58.HKD","LU0203201768.USD","LU0238689110.USD","BK4533","LU1917777945.USD","LU0256863811.USD","MHIP","LU2361044949.HKD","LU2237438978.USD","LU2462591350.SGD","SGXZ99366536.SGD","IE00B7KXQ091.USD","LU2089984988.USD","LU2264538146.SGD","LU2491050154.USD","LU1069344957.HKD","JDOC","LU2602419157.SGD","LU2108987350.USD","SG9999001176.USD","LU2112291526.USD","LU1988902786.USD","BK4007","LU2237443382.USD","LU2271345857.HKD","IE00BKPKM429.USD","SG9999015986.USD","IYH","FTXH","LU1629891620.HKD","LU2028103732.USD","LU0058720904.USD","LU2213496289.HKD","LU0158827948.USD","LU0640476718.USD","LU1868836914.USD","LU2237443895.HKD","LU2265009873.SGD","LU1093756168.USD","LU2756315318.SGD","LU0323591593.USD","LU2168564222.USD","IE00BN29S564.USD","WDNA","FHLC","IE0002141913.USD","LU0882574139.USD","SG9999018857.SGD","SG9999014914.USD","IE00B2B36J28.USD","LU2237443465.HKD","LU0354030438.USD","LU0672654240.SGD","LU2168564495.EUR","LLYZ","LU1989771016.USD","IXJ","LU0689472784.USD","IE00BWXC8680.SGD","LU0106261372.USD","IE0004445239.USD","LU0823434740.USD","SGXZ51526630.SGD","LU0964807845.USD","LU2468319806.SGD","LU2896262040.SGD","PPH","LU2491050071.SGD","LU0109394709.USD","LU0882574055.USD","TRUH","LU2456880835.USD","LU2237443549.SGD","LU0133085943.USD","BK4585","IE00B1BXHZ80.USD","LU1057294990.SGD","IE00BJLML261.HKD","IE0005OL40V9.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU2168563687.JPY","LU2237443978.SGD","LU2023251221.USD","LU2461242641.AUD","LU0266013472.USD","GDOC","LU1064131342.USD","LU1868837136.USD","RXL","LU1979441026.SGD","LU0096364046.USD","LU0353189763.USD","LU0353189680.USD","SG9999001176.SGD","LU0345770993.USD","LU0320765992.SGD","LU0316494557.USD","LU0471298694.HKD","LU2361044865.SGD","BK4581","ELIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671481209","title":"Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell","url":"https://stock-news.laohu8.com/highlight/detail?id=2671481209","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671481209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:42","pubTimestamp":1790768520,"startTime":"0","endTime":"0","summary":"Moderna's eye-watering rally has officially outpaced its fundamentals, according to one analyst, prompting a downgrade at a major Wall Street firm.Citi's Geoff Meacham cut his rating on Moderna shares","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","GDOC","IDNA","VHT","FTXH","GNOM","RXL","IXJ","PAWZ","PPH","IYH","MRNA","BMED","LGHT","MRNX","WDNA","IHE","JDOC","XLV","TRUH","FHLC","HRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671462201","title":"Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations","url":"https://stock-news.laohu8.com/highlight/detail?id=2671462201","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671462201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":"SINGAPORE and NORTH BRUNSWICK, N.J., Sept.  30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371738/0/en/adlai-nortye-appoints-christopher-liu-pharmd-as-head-of-investor-relations-and-public-relations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2298322129.HKD","BK4512","LU1861219969.SGD","BK4141","LU1548497426.USD","ONG","LU2133065610.SGD","LU1861215975.USD","ON","LU1720051017.SGD","ALN","FHLC","LU2357305700.SGD","LU1720051108.HKD","LU1854103824.USD","LU0124384867.USD","JDOC","BK4588","IE00BZ199S13.USD","LU0348723411.USD","LU0724618433.USD","ANL","LU2360107325.USD","BBP","LU1861214812.USD","ONX","IEIH","LU1854104046.USD","BK4605","LU1983260115.SGD","LU1861220033.SGD","SYNB","IE00BFMHRM44.USD","RSPH","LU1978683503.SGD","IE00BD6J9T35.USD","IBB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205985","title":"Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205985?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:45","pubTimestamp":1790765154,"startTime":"0","endTime":"0","summary":"Kenvue says post-hoc Phase III analysis links earlier 5% minoxidil use to higher hair regrowth in men with androgenetic alopeciaKenvue outlined new clinical and preclinical findings slated for present","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8jHf4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.USD","LU2089984988.USD","BK4592","IE00B2B36J28.USD","IHE","LU0792757196.USD","LU1032955483.USD","IE00B4R5TH58.HKD","LU1196500208.SGD","KVUE","LU2471134796.USD","MEDX","LU1894683348.USD","IE0002141913.USD","LU0289739699.SGD","IXJ","LU2471134952.CNY","GDOC","GLAM","LU1145028129.USD","JDOC","LU1267930573.SGD","LU0738911758.USD","LU0661504455.SGD","XLV","TRUH","PJP","BK4581","LU1778281490.HKD","IYH","LU1244550221.USD","LU2487616109.SGD","LU2236285917.USD","IE00BVYPNV92.GBP","RXL","FHLC","SG9999001440.SGD","LU0689626769.HKD","LU0787776722.HKD","SG9999001176.SGD","RSPS","LU0345770308.USD","LU1003077747.HKD","IE000WAW04H5.SGD","LU0912757837.SGD","LU0128525929.USD","FTXH","VHT","BMED","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205594","title":"Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205594?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:18","pubTimestamp":1790763483,"startTime":"0","endTime":"0","summary":"An update from Marka SA ( ($PL:MRK) ) is now available. Marka S.A. has notified investors that it has executed the twelfth installment under its am...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/marka-s-a-pays-twelfth-installment-under-amended-bondholder-arrangement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/marka-s-a-pays-twelfth-installment-under-amended-bondholder-arrangement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","LU1430594728.SGD","LU0058720904.USD","LU2125154935.USD","LU2468319806.SGD","BK4533","FHLC","LU0432979614.USD","FTXH","XLV","LU1057294990.SGD","IE00BN8TJ469.HKD","LU0689626769.HKD","HRTS","TRUH","LU1162221912.USD","LU1699723380.USD","BK4585","LU0265550946.USD","LU0162691827.USD","LU0942090050.USD","LU1941712264.USD","IE00BSNM7G36.USD","BK4559","IHE","JDOC","GDOC","LU0868494708.USD","SG9999014567.USD","MRK","RXL","SGXZ57979304.SGD","LU0203345920.USD","IXJ","LU0823416689.USD","SG9999015358.SGD","PPH","LU0472753341.HKD","IYH","LU2361045086.USD","VHT","IE00B1BXHZ80.USD","LU0070302665.USD","LU1571399168.USD","LU0069063385.USD","LU1093756168.USD","LU2125154778.USD","SG9999002224.SGD","LU1989772840.SGD","PAWZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671082132","title":"Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2671082132","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671082132?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:05","pubTimestamp":1790762710,"startTime":"0","endTime":"0","summary":"Johnson &amp; Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/09/62072451/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IE00B19Z3581.USD","LU0345769631.USD","LU1551013342.USD","JDOC","LU0072461881.USD","LU1221951129.SGD","LU0820561818.USD","LU1585245621.USD","BK4592","SG9999001176.SGD","IXJ","LU2468319806.SGD","LU1043141123.HKD","LU2213496289.HKD","LU1221951046.USD","LU1023059063.AUD","LU0234572021.USD","LU2505996509.AUD","BK4585","LU0122379950.USD","LU1983299246.USD","LU2456880835.USD","LU0787776722.HKD","XLV","MEDX","GDOC","IE000F7OJYX1.SGD","PJP","LU0234570918.USD","SG9999013999.USD","IYH","TRUH","LU2471134523.USD","FHLC","IHE","LU1506573853.SGD","IE0002141913.USD","FTXH","LU0545039389.USD","IE00BJT1NW94.SGD","LU0320765646.SGD","JNJ","LU1929549753.HKD","IE00BVYPNW00.USD","RXL","VHT","LU1196500208.SGD","LU0511384066.AUD","LU1059921491.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671089252","title":"AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2671089252","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671089252?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:55","pubTimestamp":1790762110,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PJP","LU1720051108.HKD","LU1989772923.USD","IE000F7OJYX1.SGD","IYH","LU1037948541.HKD","LU1732800096.USD","IE00B19Z3581.USD","LU1934455277.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0057025933.USD","LU1057294990.SGD","LU1670628061.USD","FTXH","LU1430594728.SGD","TRUH","LU0256863811.USD","MEDX","PPH","IE0002141913.USD","IE00B3PB1722.GBP","AGNG","LU0472753341.HKD","LU2023251221.USD","XLV","LU0395794307.EUR","IE00BJJMRZ35.SGD","FHLC","LU0029864427.USD","BK4566","BK4533","IXJ","VHT","IE000SO60NU8.SGD","LU2089284900.SGD","LU0058720904.USD","IE0000B7K699.USD","JDOC","LU2347655156.SGD","LU0203345920.USD","LU0820561909.HKD","GLAM","RXL","BK4550","LU0553294199.USD","LU0234572021.USD","IE00BLSP4452.SGD","ABBV","LU2347655073.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208859","title":"AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208859","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208859?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:51","pubTimestamp":1790761876,"startTime":"0","endTime":"0","summary":"AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan.Data showe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL9BGxfn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0417517546.SGD","IYH","LU0820561909.HKD","LU0985320562.USD","LU2357305700.SGD","JDOC","FHLC","ABBV","RXL","TRUH","LU0058720904.USD","PPH","LU0738911758.USD","XLV","LU0289739343.SGD","LU1989772923.USD","LU0289961442.SGD","LU2112291526.USD","LU1267930490.SGD","LU2237443978.SGD","LU0456855351.SGD","SG9999015952.SGD","LU1037948541.HKD","LU0069063385.USD","LU1718418525.SGD","LU1037948897.HKD","IE00BVYPNV92.GBP","LU1093756168.USD","MEDX","GLAM","IXJ","LU1430594728.SGD","LU0708994859.HKD","PJP","LU2237443622.USD","LU1983299246.USD","LU0170899867.USD","IE00B4R5TH58.HKD","VHT","LU1923622614.USD","IE00BJT1NW94.SGD","LU1934455863.HKD","LU0859254822.USD","FTXH","LU0310799852.SGD","LU0661504455.SGD","LU2125909247.SGD","LU0912757837.SGD","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270785","title":"Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270785?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4559","IE00BBT3K403.USD","IE0004445239.USD","PPH","LU1934455194.USD","LU2087621335.USD","LU0058720904.USD","JDOC","AGNG","LU1093756168.USD","LU2129689431.USD","MEDX","IE00BJJMRZ35.SGD","LU0124676726.USD","RXL","LU0320765646.SGD","LU0203347892.USD","LU0820561909.HKD","LU1839511570.USD","LU0868494617.USD","VHT","IXJ","LU0198837287.USD","LU0417517546.SGD","FHLC","FTXH","TRUH","IE00BJT1NW94.SGD","LU1236620750.USD","IE000BZT7R73.USD","LU1934455863.HKD","LU1244550494.USD","IYH","LU0949170772.SGD","LU1267930490.SGD","GLAM","SG9999015952.SGD","LU0395794307.EUR","IE00BGHQF631.EUR","LU0057025933.USD","LU0234570918.USD","LU1983299246.USD","XLV","BK4534","LU0289739343.SGD","PJP","LU1037948897.HKD","ABBV","LU0203345920.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270207","title":"Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270207?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1732800096.USD","BK4534","IYH","XLV","LU0158827948.USD","BK4139","LU2087621335.USD","LU2089283258.USD","IE00BLSP4239.USD","LU0128525929.USD","LU1244550577.SGD","IE000SO60NU8.SGD","ABBV","LU0943347566.SGD","LU0985320562.USD","RXL","TRUH","SG9999015978.USD","IE0002141913.USD","LU1989772840.SGD","FTXH","IXJ","LU1037948897.HKD","LU0795875169.SGD","LU1720051017.SGD","LU2237443549.SGD","IE00BSNM7G36.USD","PJP","IE0009355771.USD","LU0310800379.SGD","LU1267930573.SGD","MEDX","LU0395794307.EUR","IE000BZT7R73.USD","SG9999011175.SGD","GLAM","LU0545039389.USD","LU1989771016.USD","AGNG","LU2347655156.SGD","LU0289739699.SGD","LU1430594728.SGD","LU2357627491.SGD","JDOC","VHT","PPH","BK4533","LU0689626769.HKD","FHLC","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208209","title":"AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":"BRIEF-AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month PeriodSept 30 -AbbVie Inc.ABBV.N:ABBVIE: IN PHASE 1 ABBV-295 STUDY, ALL DOSING REGIMENS RESULTED IN LS MEAN WEIGHT LOSS UP TO ABOUT 10% OVER 3-MONTH TREATMENT PERIODABBVIE: 82.2% OF ALL ABBV-295 TREATED PARTICIPANTS REPORTED MILD ADVERSE EVENTS AS HIGHEST REPORTED AE SEVERITYFurther company coverage:ABBV.N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","LU1496350502.SGD","LU1839511570.USD","LU0057025933.USD","LU1732800096.USD","LU0310799852.SGD","JDOC","LU0965508806.USD","SG9999015978.USD","IXJ","LU1291159041.SGD","LU1934455277.USD","LU0820561909.HKD","LU2089984988.USD","MEDX","RXL","LU2357305700.SGD","ABBV","BK4566","LU0114720955.EUR","TRUH","IYH","IE00BSNM7G36.USD","LU0310800379.SGD","AGNG","LU0689472784.USD","LU1548497426.USD","XLV","LU0432979614.USD","IE0004445239.USD","PPH","LU1670627923.USD","PJP","LU0256863902.USD","FTXH","IE00BN8TJ469.HKD","LU0472753341.HKD","LU0158827948.USD","LU1093756168.USD","FHLC","LU0320765646.SGD","VHT","LU1983299246.USD","LU1430594728.SGD","LU2112291526.USD","GLAM","LU0098860793.USD","LU0823416689.USD","SG9999015952.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271707","title":"AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271707","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671271707?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:14","pubTimestamp":1790756080,"startTime":"0","endTime":"0","summary":"AbbVie's  phase 2 dose-finding study of zumilokibart in adults with moderate-to-severe atopic dermatitis met its primary endpoint, with all three dose regimens achieving \"significantly\" higher response rates at week 16, compared with placebo, the company said Wednesday.The mid-dose regimen has been selected for phase 3 development.The findings support further evaluation of the drug's efficacy, safety and extended dosing intervals as a potential long-term treatment option, AbbVie said.Atopic dermatitis is a condition that causes dry, itchy and inflamed skin.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","LU1934455863.HKD","LU0820561909.HKD","LU0965509010.AUD","LU0256863811.USD","IE00BDGV0183.EUR","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0965509101.SGD","LU1720051017.SGD","IYH","IE00BVYPNW00.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","FTXH","FHLC","IE000SO60NU8.SGD","LU1496350171.SGD","IE000WAW04H5.SGD","IE00B2B36J28.USD","LU2357305700.SGD","BK4550","LU0456855351.SGD","PJP","JDOC","BK4588","ABBV","IE0009355771.USD","XLV","LU1983299246.USD","TRUH","LU2023251221.USD","LU1003077747.HKD","RXL","LU0069063385.USD","SG9999015945.SGD","GLAM","LU0289739343.SGD","LU1585245621.USD","VHT","LU1670628061.USD","AGNG","LU0511384066.AUD","IXJ","LU0708994859.HKD","PPH","LU0211328371.USD","IE00BJT1NW94.SGD","LU1732800096.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176833437","title":"2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders","url":"https://stock-news.laohu8.com/highlight/detail?id=1176833437","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176833437?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:00","pubTimestamp":1790755226,"startTime":"0","endTime":"0","summary":"The 2026 Nobel Prize laureates will be announced successively from October 5 to 12. In order to understand the list of hot candidates, The Scientist published scientists' predictions for the 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIS","FXH","PJP","ELIL","CURE","RSPH","OZEM","LLYX","FHLC","NVOH","NBDS","PINK","THNR","MEDI","JDOC","NVOX","LLII","TRUH","IYH","NVOC","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671278331","title":"Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang","url":"https://stock-news.laohu8.com/highlight/detail?id=2671278331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671278331?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:32","pubTimestamp":1790746351,"startTime":"0","endTime":"0","summary":"The latest update is out from Lonza Group Ltd ( ($CH:LONN) ). Lonza has nominated pharmaceutical and biotechnology veteran Pearl Huang as an indepe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lonza-strengthens-board-with-nomination-of-biotech-veteran-pearl-huang?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lonza-strengthens-board-with-nomination-of-biotech-veteran-pearl-huang?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XT","BK4585","BK4588","FWD","AGNG","FHLC","JDOC","XBI","IEIH","SYNB","IBB","BK4581","BBP","DARP","RSPH","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220206","title":"Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:30","pubTimestamp":1790746200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUAFW3VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2089284900.SGD","SG9999015986.USD","IE00BSNM7G36.USD","LU2125909247.SGD","LU0511384066.AUD","LU2347655156.SGD","GLAM","LU1548497426.USD","LU0170899867.USD","LU0708994859.HKD","VHT","LU1551013425.SGD","LU1670627923.USD","ABBV","BK4581","IYH","LU0820561818.USD","LU1496350502.SGD","LU1496350171.SGD","LU1162221912.USD","LU1718418525.SGD","LU1929549753.HKD","LU0738911758.USD","BK4550","RXL","TRUH","JDOC","IE0009355771.USD","LU1037948541.HKD","IE0002141913.USD","LU1003077747.HKD","MEDX","LU0949170772.SGD","LU0472753341.HKD","XLV","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","AGNG","LU1720051017.SGD","PPH","LU0942090050.USD","PJP","IXJ","IE00BN8TJ469.HKD","FTXH","FHLC","LU0256863902.USD","LU1061106388.HKD","LU1093756325.SGD","LU2125909593.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220398","title":"AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220398?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:01","pubTimestamp":1790744482,"startTime":"0","endTime":"0","summary":"AbbVie presents Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis at EADV 2026AbbVie flagged new dermatology trial and real-world results slated for presentation at the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL524zqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","IE000F7OJYX1.SGD","LU1934455863.HKD","SG9999015952.SGD","VHT","LU2468319806.SGD","LU1496350171.SGD","LU0949170772.SGD","LU0738911758.USD","LU1291159041.SGD","FTXH","AGNG","PJP","LU1585245621.USD","LU2347655073.USD","LU2357627491.SGD","RXL","LU1923622614.USD","LU2133065610.SGD","LU1244550494.USD","IXJ","LU0661504455.SGD","LU2089284900.SGD","LU1057294990.SGD","LU2237443895.HKD","PPH","LU0320765646.SGD","IE00B2B36J28.USD","LU1074936037.SGD","IE00B19Z3581.USD","ABBV","IYH","LU0472753341.HKD","LU0689472784.USD","LU2237443382.USD","LU1061106388.HKD","LU0795875086.SGD","LU1718418525.SGD","MEDX","LU0417517546.SGD","LU2089283258.USD","IE000SO60NU8.SGD","LU0289739699.SGD","LU1934455277.USD","LU2129689431.USD","GLAM","JDOC","XLV","TRUH","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222612","title":"Actinogen Medical Adds Modest Number of New Shares to ASX Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671222612?lang=en_us&edition=fundamental","pubTime":"2026-09-30 11:17","pubTimestamp":1790738242,"startTime":"0","endTime":"0","summary":"Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical Limited, an ASX-listed biotechnology company, has its ordinary full...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actinogen-medical-adds-modest-number-of-new-shares-to-asx-listing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actinogen-medical-adds-modest-number-of-new-shares-to-asx-listing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LNGR","BK4588","DARP","RSPH","IEIH","AGNG","BK4585","XT","JDOC","SYNB","FHLC","FWD","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671122851","title":"Marvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2671122851","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671122851?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:32","pubTimestamp":1790721144,"startTime":"0","endTime":"0","summary":"An update from Marvel Biosciences Corp ( ($TSE:MRVL) ) is now available. Marvel Biosciences Corp., a Calgary-based pre-clinical biotechnology compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/marvel-biosciences-raises-1-6-million-to-advance-lead-neurology-drug-into-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/marvel-biosciences-raises-1-6-million-to-advance-lead-neurology-drug-into-phase-1-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","FWD","SYNB","LNGR","JDOC","BBP","DBB","IEIH","XT","BK4588","AGNG","IBB","FHLC","BK4585","DARP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224004","title":"Eli Lilly reports results from TRIUMPH-2 Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224004","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671224004?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:10","pubTimestamp":1790719814,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) and Company announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an invest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-reports-results-from-triumph-2-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-reports-results-from-triumph-2-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999014898.SGD","LU0323591593.USD","LU2491049909.HKD","LU2746668461.USD","LU2491050071.SGD","LU0823434583.USD","LU2237443382.USD","PPH","LU1629891620.HKD","JDOC","FHLC","LU1917777945.USD","LU0823434740.USD","LU0354030511.USD","LU2265009873.SGD","LU0256863811.USD","FTXH","IE00BJLML261.HKD","LU0079474960.USD","LU2089283258.USD","LU2324357040.USD","LU2750360997.AUD","SG9999017495.SGD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0786609619.USD","BK4581","LU1712237335.SGD","LU0061475181.USD","LU2361044865.SGD","LU2361045086.USD","LU0203202063.USD","SG9999014880.SGD","LU2361044949.HKD","LU2023251221.USD","SGXZ51526630.SGD","LU2237443549.SGD","LU0114720955.EUR","LU0353189763.USD","SG9999014906.USD","SGXZ99366536.SGD","IE0002141913.USD","LLY","LU0820561909.HKD","LU0964807845.USD","IE0009355771.USD","IE00B775H168.HKD","LU2552382215.SGD","LU1093756168.USD","LU0640476718.USD","IE00BJJMRX11.SGD","IE00BKDWB100.SGD","BK4588","LU0354030438.USD","SGXZ31699556.SGD","LU0122379950.USD","LU0096364046.USD","LU0210536198.USD","LU2106854487.HKD","BK4533","IE00BJJMRZ35.SGD","LU2168564065.EUR","BK4007","LU0820562030.AUD","LU0466842654.USD","LU2552382058.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU1057294990.SGD","LU2168564222.USD","IE00BFTCPJ56.SGD","LU0203201768.USD","LU0316494557.USD","LU0471298694.HKD","LU2168564495.EUR","LU2271345857.HKD","LU1127390331.HKD","AGNG","LU0385154629.USD","RXL","IE0005OL40V9.USD","LU0708995401.HKD","LU0094547139.USD","LU2756315664.SGD","LU2471134796.USD","SG9999015986.USD","LU0225283273.USD","LU0320765059.SGD","LU1814569148.SGD","LU1868837136.USD","THNR","LU2112291526.USD","OZEM","GB00BDT5M118.USD","LU1069344957.HKD","LU2471134523.USD","SG9999018857.SGD","LU2213496289.HKD","LU1868836591.USD","LU2237443978.SGD","LU2028103732.USD","LU0882574055.USD","LU2089984988.USD","LU2456880835.USD","LU2417539215.USD","IE00B2B36J28.USD","LU0234572021.USD","SGXZ57979304.SGD","LU0787776722.HKD","MHIP","LU1023059063.AUD","LLYX","IE00BWXC8680.SGD","LU0109394709.USD","LU0672654240.SGD","LU2087625088.SGD","LU0158827781.USD","LU2237438978.USD","LU0109391861.USD","LU1691799644.USD","SG9999014914.USD","LU1093756325.SGD","LU1720051108.HKD","SG9999001176.SGD","LU2896262040.SGD","IE00BFSS7M15.SGD","MEDX","LU2168564149.EUR","LU1323610961.USD","LU2237443895.HKD","WDNA","ELIS","LU2462591350.SGD","BK4599","SG9999018865.SGD","LU0256863902.USD","LU1551013425.SGD","LU2108987350.USD","LU2756315318.SGD","LU0238689110.USD","LU0345770308.USD","LU2211815571.USD","PJP","LU2462157665.USD","LU0320765992.SGD","LU0345770993.USD","LU1366192091.USD","LU2750360641.GBP","SGXZ81514606.USD","LU0820561818.USD","LLII","LU1061106388.HKD","LU1145028129.USD","LU2111349929.HKD","IE00BFSS8Q28.SGD","LU0417517546.SGD","LU2237443622.USD","LU2237443465.HKD","LU1720051017.SGD","LU1974910355.USD","IE00BKPKM429.USD","LU2491050154.USD","LU2552382132.HKD","SG9999015952.SGD","LU2746668974.SGD","LU0456855351.SGD","LU0106261372.USD","LU2063271972.USD","VHT","XLV","BK4534","LU2023250330.USD","LU1979441026.SGD","LU1548497426.USD","LU0289739699.SGD","LU0158827948.USD","HRTS","LU0943347566.SGD","LU1551013342.USD","LU0174119429.USD","LU0006306889.USD","IE00B4JS1V06.HKD","SG9999013999.USD","LU0689472784.USD","SG9999015945.SGD","SG9999001176.USD","CANC","IE0001KFT4U8.USD","IE00BJJMRY28.SGD","LU1983299246.USD","LU2468319806.SGD","LLYZ","LU0823416689.USD","LU1064131342.USD","LU1623119135.USD","IE00B7KXQ091.USD","TMED","BK4585","LU2357305700.SGD","LU1267930730.SGD","LU0471298777.SGD","LU2360106947.USD","LU1232071149.USD","LU1868836757.USD","LU1989771016.USD","LU2023250504.SGD","IHE","LU2264538146.SGD","ILDR","LU1280957306.USD","LU0882574139.USD","LU2471134952.CNY","LU2236285917.USD","GDOC","IE00B4R5TH58.HKD","IYH","LU0266013472.USD","LU0889565916.HKD","IE00B1XK9C88.USD","IE00BK4W5L77.USD","LU0432979614.USD","BK4516","LU1035775433.USD","IE00BN29S564.USD","LU1804176565.USD","LU0097036916.USD","MEDI","CURE","IE00BJT1NW94.SGD","LU0058720904.USD","LU2168563687.JPY","IE0004445015.USD","LU1988902786.USD","LU2602419157.SGD","LU1868836914.USD","LU0683600562.USD","LU2471134879.HKD","ELIL","TRUH","LU2089284900.SGD","LU2461242641.AUD","LU0133085943.USD","LU0353189680.USD","SG9999015978.USD","IE0004445239.USD","IXJ","LU1868837300.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":13,"totalSize":339,"code":"91000000","status":"200"}]}}